Overview

Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+

Status:
Unknown status

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether fractionated RIT with Epratuzumab and radiolabeled Epratuzumab are effective in the treatment of relapsing or refractory ALL.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Nantes University Hospital

Treatments:

Epratuzumab